Comparison Between Quadro-iliac Plane Block (QIPB) and Supra-Inguinal Fascia Iliaca Compartment Block (S-FICB) for Total Hip Arthroplasty
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Quadro iliac Plane Block(QİPB), supra-inguinal fascia iliaca compartment block (S-FICB).
- Who it may be relevant to
- Registry conditions: Quadro-Iliac Plane Block, Supra-inguinal Fascia Iliaca Block, Hip Arthroplasty, Total, Pain Management. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparison Between Quadro-iliac Plane Block (QIPB) and Supra-Inguinal Fascia Iliaca Compartment Block (S-FICB) for Total Hip Arthroplasty: a Randomized Controlled Trial
Overview
This randomized clinical trial aims to evaluate and compare the analgesic efficacy and functional outcomes of the quadro-iliac plane block (QIPB) and the supra-inguinal fascia iliaca compartment block (S-FICB) in patients undergoing total hip arthroplasty. The primary outcome is the Numeric Rating Scale (NRS) within the first 48 hours after surgery. Secondary outcomes include postoperative total opioid consumption, ıncidence of quadriceps motor block, time to first ambulation, block performance time, falls, length of hospital stay, block- related complications(hematoma,local anesthetic systemic complications, vascular puncture, and infection), patient satisfaction assessed using a Likert scale, and incidence of postoperative nausea and vomiting.
Detailed description
Materials and Methods:
This prospective, randomized clinical trial will include patients aged 18-80 years with American Society of Anesthesiologists (ASA) physical status I-III who are scheduled to undergo elective unilateral primary total hip arthroplasty unde spinal anesthesia. Before enrollment, all patients will be informed about the study protocol and written informed consent will be obtained. Patients will be instructed on the use of the Numeric Rating Scale (NRS) for postoperative pain assessment, where 0 represents no pain and 10 represents the worst pain imaginable. Patients with contraindications to spinal anesthesia, allergy to local anesthetics, coagulopathy, infection at the injection site, chronic opioid use, pre-existing neurological deficits involving the lower extremities, cognitive impairment preventing reliable communication, revision or bilateral hip arthroplasty, and refusal to participate will be excluded from the study. Patients will be randomly allocated to one of two study groups using a computer-generated randomization sequence (https://www.randomizer.org). Randomization will be performed by a team member not involved in patient management or outcome assessment. Allocation concealment will be achieved using sequentially numbered sealed opaque envelopes, which will be opened immediately before block performance. Upon arrival in the operating room, standard monitoring including electrocardiography, non-invasive blood pressure measurement, and pulse oximetry will be applied. Following intravenous access and preloading according to institutional practice, spinal anesthesia will be performed at the L3-L4 or L4-L5 intervertebral space using a 25-gauge Quincke spinal needle under aseptic conditions. After confirmation of free cerebrospinal fluid flow, 12-15 mg of 0.5% hyperbaric bupivacaine will be administered intrathecally. Supplemental sedation with intravenous midazolam and/or propofol may be provided when required for patient comfort.
Following successful spinal anesthesia, patients will receive either ultrasound- guided quadro-iliac plane block (QIPB) or supra-inguinal fascia iliaca compartment block (S-FICB) according to group allocation. All blocks will be performed by anesthesiologists experienced in regional anesthesia and familiar with both techniques.
All patients will receive the same multimodal postoperative analgesic regimen and standardized postoperative rehabilitation protocol. Postoperative pain scores at rest and during movement will be assessed using the NRS during the first 48 postoperative hours. Opioid consumption, incidence of quadriceps motor block, time to first ambulation, patient satisfaction, postoperative nausea and vomiting, falls, length of hospital stay, block performance time, and block-related complications will also be recorded.
Outcome assessments will be performed by investigators who are unaware of group allocation.
Interventions
- Procedure Quadro iliac Plane Block(QİPB)
Participants allocated to the QIPB group will receive an ultrasound-guided quadro-iliac plane block after spinal anesthesia. Following standard aseptic preparation, 30 mL of 0.25% bupivacaine will be administered into the target fascial plane under ultrasound guidance after confirming the absence of blood on aspiration. - Procedure supra-inguinal fascia iliaca compartment block (S-FICB)
Participants allocated to the S-FICB group will receive an ultrasound-guided quadro-iliac plane block after spinal anesthesia. Following standard aseptic preparation, 30 mL of 0.25% bupivacaine will be administered into the target fascial plane under ultrasound guidance after confirming the absence of blood on aspiration.
Primary outcome measures
- Postoperative pain scores [Time frame: Postoperative 6, 24, 36, and 48 hours]
Secondary outcome measures (9)
- Postoperative opioid consumption [Time frame: Postoperative 24 and 48 hours]
- Incidence of quadriceps motor block [Time frame: Postoperative 3, 6, and 24 hours]
- Time to first ambulation [Time frame: Time from the end of surgery to the first successful ambulation.]
- Patient satisfaction [Time frame: Postoperative 48 hours]
- Postoperative nausea and vomiting (PONV) [Time frame: Postoperative 48 hours]
- Block performance time [Time frame: Periprocedural]]
- Falls [Time frame: Through postoperative day 2]
- Length of hospital stay [Time frame: Through hospital discharge, up to 30 days]
- Block-related complications [Time frame: Through hospital discharge, up to 30 days]
Eligibility criteria
Inclusion criteria
- Age between 18 and 80 years
- American Society of Anesthesiologists physical status I-III
- Scheduled for elective unilateral primary total hip arthroplasty
- Surgery planned under spinal anesthesia
- Ability to understand and use the Numeric Rating Scale
- Written informed consent provided
Exclusion criteria
- Refusal to participate
- Revision total hip arthroplasty
- Bilateral total hip arthroplasty
- Contraindication to spinal anesthesia
- Contraindication to peripheral nerve block
- Known allergy to local anesthetics or study drugs
- Coagulopathy or anticoagulant use incompatible with neuraxial/regional anesthesia
- Infection at the block injection site
- Pre-existing neurological deficit involving the operative lower extremity
- Peripheral neuropathy
- Chronic opioid use
- Cognitive impairment or inability to communicate reliably
- Severe hepatic or renal failure
- Body mass index >35 kg/m²
- Pregnancy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07667218 · QİPB vs S-FICB